Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-57.59M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -71.54% |
| Return on Assets (Trailing 12 Months) | -64.94% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.63 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.63 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.42 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.66 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 21.88M |
| Free Float | 17.99M |
| Market Capitalization | $147.72M |
| Average Volume (Last 20 Days) | 0.12M |
| Beta (Past 60 Months) | 3.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.80% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |